x

Drug Discovery Solutions

Ncardia combines cardiovascular and neural cell expertise with commercial iPSC manufacturing experience to provide you with predictive and translational assays at any throughput. Our integrated Drug Discovery platform gives you a flexible solution to integrate hiPSC disease models into your cardiac and neuronal drug discovery campaigns, tailored to your project needs.

Bringing predictive and translational human disease biology early into your drug discovery pipeline

Disease modeling icon

Disease modeling

Large-scale manufacturing icon

Large-scale manufacturing

Assay development icon

Assay development

High-throughput screening icon

High-throughput screening

Disease Modeling

Developing hiPSC-derived cardiac and neuronal disease models of your choice

The utility of a cell-based disease model relies upon generation of a demonstrable phenotype that closely reflects the underlying biology of the disease. We develop human iPSC-derived cardiac and neuronal disease models of your choice, depending on your requirements to enable target or phenotypic drug discovery, as well as guiding structure-activity relationship (SAR) studies.

 

Patient-derived: Cardiomyocytes bearing physiologically relevant functional phenotypes can be generated from an individual with a genetic, ethnic or disease background.

Induced: Disease phenotypes can be induced in "healthy" cells through utilization of disease-relevant stimuli.

CRISPR-edited: Targeted CRISPR/Cas9 gene editing enables the rapid creation of cell lines containing disease-associated mutations.

 

Large-scale manufacturing

Consistent, high-quality large-scale manufacturing of functional hiPSC-derived cells is key to implement phenotypic disease models in drug discovery.

Our bioprocessing pipeline is comprised of state-of-the-art bioreactor systems to assess and optimize critical process parameters at small scale, validate conditions at mid scale, and manufacture at 3-10 L scale in an automated closed system.

We described how controlled cell manufacturing can enable high-throughput phenotypic screening in a whitepaper, created in collaboration with Eppendorf.

Read the whitepaper

Assay Development

Ncardia is equipped with in-house readout systems to develop physiologically relevant hiPSC-based phenotypic assays

We select optimal disease assay conditions in combination with appropriate high-content readouts following expert evaluation of assay performance parameters, including S/B ratio and assay window.

Reproducibility is crucial for a successful compound screening. We assess key assay parameters such as Z-factor, coefficient variation of controls and Pearson correlation of replicates between plates with a small set of reference compounds. Qualified assays are released for subsequent drug screening.

Explore our assay services

High-throughput screening

Successful drug efficacy screening and validation requires a physiologically relevant cell model and validated high throughput screening protocols to efficiently screen drug candidates.

Our integrated Drug Discovery platform features a fully automated high-througput screening platform for lead identification, hit-confirmation and dose-response curve generation. The platform includes miniaturization into 384-well format and automated cell culturing, qualification of screening plates, high content data acquisition, analysis and reporting.

We have used automated cell culture and screening system to screen >3,500 small molecules in a chemically induced hypertrophy disease model, using a validated phenotypic assay. You can read more about this project in our whitepaper:

Read the whitepaper

Project process

Through our integrated Drug Discovery platform, we can develop innovative high throughput drug efficacy screenings for a broad spectrum of cardiac and neural applications. We help you assess the efficacy of your compounds, step by step, to get you the results you need.

We recently applied our process to create and screen on a hypertrophic cardiomyopathy model, utilizing hiPSC-derived cardiomyocytes.

Read the case study

 

Integrated drug discovery platform process flow